Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Late-Onset Myasthenia Graivs,A Changing Scene
Arch Neurol 56:25-27, Aarli,J.A., 1999
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Total Body Irradiation for Myasthenia Gravis:A Long-Term Follow-up
Neurol 43:2215-2221, Durelli,L.,et al, 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978
Function of Circulating Antibody to Acetylcholine Receptor in Myasthenia Gravis:Investigation by Plasma Exchange
Neurol 28:266, Newsom-Davis,J.,et al, 1978
Plasmapheresis & Immunosuppressive Drug Therapy in Myasthenia Gravis
NEJM 297:1134, Dau,P.C.,et al, 1977